Verrica Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Verrica Pharmaceuticals Inc. (VRCA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $27.70 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $27.70.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $28.60.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $40.76.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $47.50.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $27.70 10-Q · filed 2026-08-06 |
| 2026-03-31 | $28.60 10-Q · filed 2026-05-12 |
| 2025-12-31 | $40.76 10-K · filed 2026-03-11 |
| 2025-09-30 | $47.50 10-Q · filed 2025-11-14 |
| 2025-06-30 | $62.75 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.73 10-Q · filed 2025-05-13 |
| 2024-09-30 | $8.96 10-Q · filed 2024-11-05 |
| 2024-06-30 | $8.99 10-Q · filed 2024-08-14 |
| 2024-03-31 | $9.01 10-Q · filed 2024-05-13 |
| 2023-09-30 | $9.12 10-Q · filed 2023-11-09 |
| 2023-06-30 | $9.13 10-Q · filed 2023-08-08 |
| 2023-03-31 | $9.08 10-Q · filed 2023-05-09 |
| 2022-09-30 | $8.98 10-Q · filed 2022-11-07 |
| 2022-06-30 | $9.10 10-Q · filed 2022-08-11 |
| 2022-03-31 | $8.90 10-Q · filed 2022-05-09 |
| 2021-09-30 | $8.92 10-Q · filed 2021-11-12 |
| 2021-06-30 | $9.04 10-Q · filed 2021-08-10 |
| 2021-03-31 | $8.99 10-Q · filed 2021-05-07 |
| 2020-09-30 | $8.01 10-Q · filed 2020-11-09 |
| 2020-06-30 | $7.93 10-Q · filed 2020-08-05 |
| 2020-03-31 | $7.77 10-Q · filed 2020-05-07 |
| 2019-06-30 | $6.66 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |